CD38 and rheumatoid arthritis: Thus, the functional presence of plasmablasts/cells in synovial niches together with the high expression of genes involved in their development and survival indicates that therapeutic targeting of antibody-producing plasma cells/plasmablasts with these molecules, in particular CD38, could be a viable strategy for disease intervention in patients with arthralgia to prevent progression to established RA.